Home LiteratureArticle Details
PMID: 1870202 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.

Journal of virology ·Vol. 65 ·No. 9 ·1991-09-00 ·Pages 4777-85

McKeating J, Balfe P, Clapham P, Weiss RA

Abstract

Variants of molecularly cloned human immunodeficiency virus type 1 (HIV-1) were analyzed following selection for the ability to replicate after exposure to soluble, recombinant CD4 protein (rCD4). Two variants, 4/1 and 16/2, show 8-fold and 16-fold reduced sensitivity to rCD4 neutralization yet remain as sensitive as the parental wild-type (wt) virus to neutralization by rCD4-immunoglobulin G (IgG) chimeric molecules and to inhibition of cellular infection by anti-CD4 antibody. The 4/1 variant is more cytopathic, with faster cell fusion and replication kinetics than the wt virus. The gp120s derived from the 4/1 and 16/2 variants have 3-fold and 30-fold reduced binding affinities to rCD4, respectively. The 4/1 variant exhibits diminished shedding of virion gp120 induced by rCD4. The binding of and neutralization by V3 loop antibodies and other anti-gp120 antibodies is reduced for 4/1 but not for 16/2. Sequence analysis revealed a codon change at amino acid residue 435 in the C4 region of the gp120 of 16/2. This accounts for its rCD4 insensitivity, since the insertion of this mutation in the wt gp120 yields the same phenotype. The 4/1 variant has a codon change in the V3 region of gp120 (amino acid 311), which accounts for its reduced sensitivity to some neutralizing antibodies but not to rCD4. The ready selection of rCD4-resistant variants has obvious relevance for rCD4-based therapeutic stratagems.

MeSH Terms
Amino Acid Sequence CD4 Antigens/genetics,metabolism Cell Fusion Cytopathogenic Effect, Viral HIV Antibodies/immunology HIV Envelope Protein gp120/genetics,immunology,metabolism HIV-1/growth & development,metabolism Humans In Vitro Techniques Molecular Sequence Data Mutation Neutralization Tests Protein Binding Recombinant Proteins/chemistry,metabolism Solubility Structure-Activity Relationship Virus Replication
Chemicals
CD4 Antigens HIV Antibodies HIV Envelope Protein gp120 Recombinant Proteins
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
McKeating J
Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom.
Balfe P
Clapham P
Weiss R A
References (54)
54 references, click to expand
  1. Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations.
    J Virol. 1990 Dec;64(12):6221-33 PMID: 2123011
  2. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.
    Cell. 1986 Nov 7;47(3):333-48 PMID: 3094962
  3. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.
    J Virol. 1991 Jan;65(1):489-93 PMID: 1702163
  4. Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.
    J Exp Med. 1990 Oct 1;172(4):1233-42 PMID: 1698911
  5. Soluble CD4 enhances simian immunodeficiency virus SIVagm infection.
    J Virol. 1990 Dec;64(12):6252-6 PMID: 1700834
  6. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
    J Virol. 1991 Feb;65(2):852-60 PMID: 1898972
  7. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    J Virol. 1991 Mar;65(3):1133-40 PMID: 1995942
  8. Poliovirus mutants resistant to neutralization with soluble cell receptors.
    Science. 1990 Dec 14;250(4987):1596-9 PMID: 2177226
  9. Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
    Science. 1990 Nov 23;250(4984):1139-42 PMID: 2251501
  10. Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.
    AIDS Res Hum Retroviruses. 1990 Oct;6(10):1209-12 PMID: 2252640
  11. Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester.
    Virology. 1987 May;158(1):44-51 PMID: 3107214
  12. Characterization of HIV-1 neutralization escape mutants.
    AIDS. 1989 Dec;3(12):777-84 PMID: 2483618
  13. Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120.
    J Immunol. 1989 Sep 15;143(6):1832-6 PMID: 2476484
  14. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120.
    J Virol. 1989 Sep;63(9):3579-85 PMID: 2474670
  15. Single amino-acid changes in HIV envelope affect viral tropism and receptor binding.
    Nature. 1989 Aug 17;340(6234):571-4 PMID: 2475780
  16. Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.
    J Virol. 1988 Oct;62(10):3695-702 PMID: 2458487
  17. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.
    J Virol. 1988 Dec;62(12):4703-11 PMID: 2460639
  18. The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule.
    AIDS. 1988 Apr;2(2):101-5 PMID: 2454642
  19. Neutralizing monoclonal antibodies to the AIDS virus.
    AIDS. 1988 Feb;2(1):25-9 PMID: 2451922
  20. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.
    Cell. 1987 Sep 11;50(6):975-85 PMID: 2441877
  21. Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions.
    Virology. 1985 Dec;147(2):326-35 PMID: 2416116
  22. Evaluation of human and simian immunodeficiency virus plaque and neutralization assays.
    J Gen Virol. 1989 Dec;70 ( Pt 12):3327-33 PMID: 2575137
  23. Identification of the residues in human CD4 critical for the binding of HIV.
    Cell. 1989 May 5;57(3):469-81 PMID: 2541915
  24. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.
    Nature. 1989 Jan 26;337(6205):368-70 PMID: 2536142
  25. Studies with crosslinking reagents on the oligomeric structure of the env glycoprotein of HIV.
    Virology. 1989 Sep;172(1):367-9 PMID: 2672564
  26. An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide.
    Nucleic Acids Res. 1989 Feb 11;17(3):1266 PMID: 2922271
  27. An improved sequencing method using Sequenase that is independent of template concentration.
    Nucleic Acids Res. 1988 Jul 11;16(13):6238 PMID: 3399400
  28. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
    Anal Biochem. 1987 Apr;162(1):156-9 PMID: 2440339
  29. Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding.
    J Virol. 1989 Oct;63(10):4464-8 PMID: 2550679
  30. An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1.
    AIDS. 1989 Mar;3(3):155-63 PMID: 2540772
  31. The CD4 antigen: physiological ligand and HIV receptor.
    Cell. 1988 Mar 11;52(5):631-3 PMID: 2830988
  32. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide.
    Virology. 1988 Jul;165(1):209-15 PMID: 2838959
  33. Escherichia coli sbcC mutants permit stable propagation of DNA replicons containing a long palindrome.
    Gene. 1988 Nov 15;71(1):201-5 PMID: 2975250
  34. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.
    Science. 1985 Aug 9;229(4713):563-6 PMID: 2992081
  35. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.
    J Virol. 1989 Jun;63(6):2674-9 PMID: 2786089
  36. A soluble form of CD4 (T4) protein inhibits AIDS virus infection.
    Nature. 1988 Jan 7;331(6151):82-4 PMID: 3257544
  37. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):767-8 PMID: 6083454
  38. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7 PMID: 6096719
  39. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.
    Science. 1987 Sep 11;237(4820):1351-5 PMID: 3629244
  40. A new method for estimating synonymous and nonsynonymous rates of nucleotide substitution considering the relative likelihood of nucleotide and codon changes.
    Mol Biol Evol. 1985 Mar;2(2):150-74 PMID: 3916709
  41. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.
    J Virol. 1990 Feb;64(2):864-72 PMID: 2296085
  42. A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site.
    Cell. 1990 Mar 9;60(5):747-54 PMID: 2107024
  43. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
    AIDS. 1990 Apr;4(4):307-15 PMID: 2190605
  44. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.
    AIDS. 1990 Apr;4(4):297-305 PMID: 2190604
  45. CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type 2-infected lymphoid cells.
    J Virol. 1990 Oct;64(10):5194-8 PMID: 2398542
  46. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Proc Natl Acad Sci U S A. 1990 Sep;87(17):6574-8 PMID: 2395859
  47. HIV requires multiple gp120 molecules for CD4-mediated infection.
    Nature. 1990 Jul 19;346(6281):277-9 PMID: 2374593
  48. The N-terminal region of the human immunodeficiency virus envelope glycoprotein gp120 contains potential binding sites for CD4.
    Proc Natl Acad Sci U S A. 1990 May;87(10):3695-9 PMID: 2339113
  49. Enhancement of SIV infection with soluble receptor molecules.
    Science. 1990 Mar 2;247(4946):1084-8 PMID: 2309120
  50. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.
    Proc Natl Acad Sci U S A. 1990 Jan;87(2):648-52 PMID: 2300552
  51. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
    Ann Intern Med. 1990 Feb 15;112(4):254-61 PMID: 2297204
  52. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.
    Ann Intern Med. 1990 Feb 15;112(4):247-53 PMID: 2297203
  53. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.
    J Virol. 1990 Dec;64(12):5701-7 PMID: 2243375
  54. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1990 Dec;64(12):5840-50 PMID: 2243378
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1991-09-00
Pages
4777-85
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC248935
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]